Barclays Raises Acceleron Price Target On Positive Luspatercept Data
June 13, 2016 at 10:10 AM EDT
Barclays has raised the price target of Acceleron Pharma Inc (NASDAQ: XLRN) shares to $42 (18.5 percent upside) from $40, based on a ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.